Zhejiang Sunflower Light Energy - Asset Resilience Ratio
Zhejiang Sunflower Light Energy (300111) has an Asset Resilience Ratio of 3.06% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Zhejiang Sunflower Light Energy total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2008–2022)
This chart shows how Zhejiang Sunflower Light Energy's Asset Resilience Ratio has changed over time. See 300111 net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Zhejiang Sunflower Light Energy's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 300111 market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥30.02 Million | 3.06% |
| Total Liquid Assets | CN¥30.02 Million | 3.06% |
Asset Resilience Insights
- Limited Liquidity: Zhejiang Sunflower Light Energy maintains only 3.06% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Zhejiang Sunflower Light Energy Industry Peers by Asset Resilience Ratio
Compare Zhejiang Sunflower Light Energy's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535 |
Drug Manufacturers - Specialty & Generic | 9.09% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.02% |
|
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
Annual Asset Resilience Ratio for Zhejiang Sunflower Light Energy (2008–2022)
The table below shows the annual Asset Resilience Ratio data for Zhejiang Sunflower Light Energy.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-12-31 | -0.12% | CN¥-723.79K ≈ $-105.91K |
CN¥616.25 Million ≈ $90.18 Million |
-0.12pp |
| 2021-12-31 | 0.00% | CN¥2.00K ≈ $292.66 |
CN¥631.63 Million ≈ $92.43 Million |
+0.23pp |
| 2020-12-31 | -0.23% | CN¥-1.28 Million ≈ $-187.15K |
CN¥564.44 Million ≈ $82.60 Million |
+0.22pp |
| 2019-12-31 | -0.45% | CN¥-3.11 Million ≈ $-454.84K |
CN¥694.03 Million ≈ $101.56 Million |
+0.14pp |
| 2018-12-31 | -0.58% | CN¥-8.50 Million ≈ $-1.24 Million |
CN¥1.46 Billion ≈ $213.11 Million |
-1.41pp |
| 2012-12-31 | 0.83% | CN¥25.09 Million ≈ $3.67 Million |
CN¥3.04 Billion ≈ $444.47 Million |
-2.45pp |
| 2011-12-31 | 3.28% | CN¥116.41 Million ≈ $17.03 Million |
CN¥3.55 Billion ≈ $519.44 Million |
+0.53pp |
| 2010-12-31 | 2.75% | CN¥77.40 Million ≈ $11.33 Million |
CN¥2.81 Billion ≈ $411.37 Million |
+1.51pp |
| 2008-12-31 | 1.25% | CN¥20.00 Million ≈ $2.93 Million |
CN¥1.60 Billion ≈ $234.81 Million |
-- |
About Zhejiang Sunflower Light Energy
Zhejiang Sunflower Great Health Co., Ltd. engages in the research, development, production, and sale of anti-infectious, cardiovascular, digestive system and other drugs in China and internationally. It offers clarithromycin API and tablets, anti-infective drugs used for nasopharyngeal infection, lower respiratory tract infection, skin and soft tissue infection, acute otitis media, Mycoplasma pne… Read more